Physician profile
Robert M Rotche
NPI 1417924101
$7,933.21
in general payments reported to CMS, 2019-2025
40 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,552 · 2020: $325 · 2021: $301 · 2022: $242 · 2023: $3,146 · 2024: $172 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,730 · Food and Beverage: $585 · Travel and Lodging: $166 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,730.00 |
| Food and Beverage | $585.45 |
| Travel and Lodging | $166.37 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,049.32 | 2019-2024 | Tecvayli, Carvykti, Darzalex |
| Astrazeneca Pharmaceuticals LP | $2,899.35 | 2019-2023 | Lynparza, Imfinzi |
| Incyte Corporation | $570.48 | 2019-2025 | Jakafi, Monjuvi |
| Pfizer INC. | $168.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $147.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $98.33 | 2019-2024 | Opdivo |
| Tactile Systems Technology INC | $89.63 | 2022 | |
| Seagen INC. | $61.45 | 2020-2021 | |
| Gilead Sciences, INC. | $51.41 | 2021-2025 | Trodelvy |
| Abbvie INC. | $46.54 | 2019-2025 | |
| Amgen INC. | $44.37 | 2021-2023 | Lumakras |
| Genzyme Corporation | $41.08 | 2021-2023 | |
| Beigene USA, INC. | $36.00 | 2021-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $35.18 | 2021-2023 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $34.74 | 2019-2024 | Tazverik |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rotche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.